Gyre Therapeutics, Inc. GYRE Purchases of equity securities
Purchases of equity securities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireEquityMethodInvestments.
The official record: Gyre Therapeutics, Inc.’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s purchases of equity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s purchases of equity securities?
- Gyre Therapeutics, Inc. (GYRE) reported purchases of equity securities of $421.5K in Q4 2024.
- How has Gyre Therapeutics, Inc.'s purchases of equity securities changed year-over-year?
- Gyre Therapeutics, Inc.'s purchases of equity securities increased by 68.6% year-over-year, from $250K to $421.5K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s purchases of equity securities?
- Over 2 years (2022 to 2024), Gyre Therapeutics, Inc.'s purchases of equity securities has grown at a 12.5% compound annual growth rate (CAGR), from $1.33M to $1.69M.
- What does purchases of equity securities mean?
- Cash spent purchasing equity securities for the investment portfolio.